JESSICA KAREN WONG M.D
Prescription History 1306226352
Radiology - Radiation Oncology in Philadelphia, PA
Quality Rating: 76.7 out of 100 score
NPI Status: Active since June 04, 2015
Contact Information
333 COTTMAN AVE
PHILADELPHIA, PA
ZIP 19111
Phone: (215) 728-2581
Fax: (215) 214-4038
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JESSICA KAREN WONG M.D, an active Radiation Oncology specialist practicing in Philadelphia, PA. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 272 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 248 claims alone.
Alfuzosin Hcl Er
Generic Formulation: Alfuzosin HclSpecialty: Radiation OncologyProvider Avg Cost Per Claim
$11.95
State Avg Cost Per Claim
$31.43
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
Alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Alfuzosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.
Tamsulosin Hcl
Generic Formulation: Tamsulosin HclSpecialty: Radiation OncologyProvider Avg Cost Per Claim
$23.67
State Avg Cost Per Claim
$19.27
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JESSICA KAREN WONG M.D provides transparency into local medical care patterns within Philadelphia, PA.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Radiation Oncology** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
